Atlas Trials

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Clinical trial NCT04080804 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04080804
Sponsor
Dan Zandberg
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma (HNSCC)
Start date
2019-12-20
Primary completion
2027-10-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.